ABM Therapeutics Inc. presented a novel small-molecule, ATP-uncompetitive, phosphorylated MEK (pMEK) inhibitor – ABM-4095 – that potently prevents phosphorylation of MEK by RAF with moderate inhibition of MEK kinase activity; it is being investigated for the potential treatment of pancreatic cancer.
At the AACR meeting, Innovent Biologics Inc. discussed the discovery and preclinical evaluation of a B7-H3/EGFR bispecific antibody-drug conjugate (bsADC).
“Hot and cold tumors may need different types of immunotherapy,” Jay Berzofsky told the audience as the American Association for Cancer Research’s (AACR) 2024 annual meeting kicked off this weekend. In an educational session on cancer vaccines, Berzofsky, who is head of the National Cancer Institute’s Molecular Immunogenetics and Vaccine Research section, explained that when immunotherapy fails in hot tumors, it fails despite the existence of an immune response, due to an immunosuppressive microenvironment.
Pfizer Inc. has presented preclinical data on its first-in-class, selective cyclin-dependent kinase 4 (CDK4) inhibitor compound, PF-07220060, that has shown 20-fold and 4-fold increased selectivity for CDK4 vs. CDK6 compared to palbociclib and abemaciclib/ribociclib, respectively.
It has been previously demonstrated that B7-H3 and EGFR are co-expressed in multiple solid tumors. At the ongoing AACR meeting in San Diego, researchers from Innovent Biologics Inc. presented preclinical data for their bispecific antibody (bsAb), IBI-334, against B7-H3 and EGFR.
Kinase inhibitors have emerged as crucial cancer therapeutics due to the involvement of kinases in cancer signaling. At the AACR, Neosome Life Sciences LLC has provided data on their kinase inhibitor NEOS-223 for the potential treatment of tumors. The compound was tested in several cancer cell types, as well as in in vivo cancer models in mice.
As with most common diseases of the developed world, aging is the major risk factor for developing cancer. Most of the half-dozen hallmarks of precancer that were published last week by investigators from Vanderbilt University and the Fred Hutchinson Cancer Research Center are also hallmarks of aging.
Unfortunately, scientists reported at the American Association for Cancer Research’s (AACR) 2024 annual meeting this week that accelerated aging is increasing, and may be driving an increase in early-onset cancers.
New and updated clinical data presented by biopharma firms at the AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics
, including: Aprea, Aulos, Avistone, Beyond Cancer, Black Diamond, Cogent, Omega, Ose, Puma, Revolution, Verastem.
New and updated clinical data presented by biopharma firms at the American Association for Cancer Research annual meeting, including: Innovent, Primmune.
New and updated clinical data presented by biopharma firms at the American Association for Cancer Research annual meeting, including: Beigene, Cellular Invlos, Karyopharm, Kinnate, Mapkure, Mendus, Mink, Nouscom, Relay, Repare, Scancell, Sonnet, Springworks, Transgene, Triumvira.
RSS
